Differential expression of metabotropic glutamate receptors 2 and 3 in schizophrenia: a mechanism for antipsychotic drug action?
about
Group II Metabotropic Glutamate Receptors as Targets for Novel Antipsychotic DrugsPositive allosteric modulators of metabotropic glutamate 2 receptors in schizophrenia treatmentPerspectives on the mGluR2/3 agonists as a therapeutic target for schizophrenia: Still promising or a dead end?Serotonergic hallucinogens as translational models relevant to schizophrenia.GABA transporter-1 deficiency confers schizophrenia-like behavioral phenotypes.Targeting glutamate synapses in schizophreniaNAAG peptidase inhibitors block cognitive deficit induced by MK-801 and motor activation induced by d-amphetamine in animal models of schizophrenia.Consensus paper of the WFSBP Task Force on Biological Markers: Criteria for biomarkers and endophenotypes of schizophrenia part II: Cognition, neuroimaging and genetics.mGluR2/3 agonist LY379268 rescues NMDA and GABAA receptor level deficits induced in a two-hit mouse model of schizophrenia.Pharmacogenetic associations of the type-3 metabotropic glutamate receptor (GRM3) gene with working memory and clinical symptom response to antipsychotics in first-episode schizophreniaAssociation of variants in DRD2 and GRM3 with motor and cognitive function in first-episode psychosisThe glutamate hypothesis of schizophrenia: evidence from human brain tissue studies.Extracellular matrix abnormalities in schizophreniaPharmacological activation of group-II metabotropic glutamate receptors corrects a schizophrenia-like phenotype induced by prenatal stress in mice.Neurochemical Metabolomics Reveals Disruption to Sphingolipid Metabolism Following Chronic Haloperidol AdministrationN-acetylaspartylglutamate (NAAG) and N-acetylaspartate (NAA) in patients with schizophreniaCOMT val158met polymorphism and molecular alterations in the human dorsolateral prefrontal cortex: Differences in controls and in schizophreniaLocalization of NAAG-related gene expression deficits to the anterior hippocampus in schizophreniaGroup II metabotropic glutamate receptors and schizophrenia.Metabotropic glutamate receptor 3 (mGlu3; mGluR3; GRM3) in schizophrenia: Antibody characterisation and a semi-quantitative western blot study.mGluR2/3 mechanisms in primate dorsolateral prefrontal cortex: evidence for both presynaptic and postsynaptic actions.A review of neurobiological vulnerability factors and treatment implications for comorbid tobacco dependence in schizophrenia.Serotonin-glutamate and serotonin-dopamine reciprocal interactions as putative molecular targets for novel antipsychotic treatments: from receptor heterodimers to postsynaptic scaffolding and effector proteins.mGluR2 positive allosteric modulators: a patent review (2009 - present).Glutamate receptor abnormalities in schizophrenia: implications for innovative treatments.The glutamatergic aspects of schizophrenia molecular pathophysiology: role of the postsynaptic density, and implications for treatmentIn the grey zone between epilepsy and schizophrenia: alterations in group II metabotropic glutamate receptors.mGluR2 versus mGluR3 Metabotropic Glutamate Receptors in Primate Dorsolateral Prefrontal Cortex: Postsynaptic mGluR3 Strengthen Working Memory Networks.Molecular determinants of positive allosteric modulation of the human metabotropic glutamate receptor 2.Fractionation of spatial memory in GRM2/3 (mGlu2/mGlu3) double knockout mice reveals a role for group II metabotropic glutamate receptors at the interface between arousal and cognition.Neuronal activity patterns in the mediodorsal thalamus and related cognitive circuits are modulated by metabotropic glutamate receptors.D2 receptor genetic variation and clinical response to antipsychotic drug treatment: a meta-analysis.Update on the neurobiology of schizophrenia: a role for extracellular microdomains.The mGluR2/3 agonist LY379268 reverses post-weaning social isolation-induced recognition memory deficits in the rat.Unique Molecular Regulation of Higher-Order Prefrontal Cortical Circuits: Insights into the Neurobiology of Schizophrenia.Power spectrum scale invariance identifies prefrontal dysregulation in paranoid schizophrenia.Neonatal exposure to MK-801 reduces mRNA expression of mGlu3 receptors in the medial prefrontal cortex of adolescent rats.Age-Related Declines in Prefrontal Cortical Expression of Metabotropic Glutamate Receptors that Support Working Memory.
P2860
Q26744729-DF83E207-8CD7-4AC1-960A-125BC7212896Q26852047-DB0B74E5-B3E8-44A8-85FC-41A85391B870Q30379983-3F922371-808D-4E67-B0D0-897113252326Q30427074-8E1DEDFE-6951-4903-B18A-A6B24BC4EA8FQ30451228-B23F4227-C454-482D-9F06-DC9F1E865F4DQ30460392-FE5651DE-42E9-4402-B914-3CB60088B52EQ30465008-3C180FC4-0AB7-4DAB-85D2-438BEF65D9AAQ31108616-C92F9F05-139B-485F-BFF1-DC141695898EQ34513221-5B340ADA-BDBD-47C3-8F01-81CA74080D86Q34807152-616D9271-DD9B-4208-BA26-3E73D167E080Q34913690-F4560804-F17B-4FF3-AC24-6635C7E58787Q35186635-7F891C14-388D-453C-B2E7-65699E279F86Q35603175-75026DCB-857E-4514-8104-F8C678E1955CQ35760210-6A2D1A4D-E7CA-4D2C-9D3D-7DDEC8863FACQ35987580-B336CDBB-6A8C-4082-A97E-284EECE818D5Q36471469-D4B4DC83-A7DD-4FA1-9229-555DC3165E6FQ36813596-A4317331-2C71-4167-95BA-69A1EA37F413Q37199826-6BFFE7EE-E3DD-4B3D-9A6F-EE0E57B0E041Q37473779-5CC4B669-00C2-4BF9-82AF-C775890FD0DCQ37486473-8EB054BF-1F6D-40FC-B06B-4889C6020F90Q37632867-07405E98-6B64-4346-AB7D-8E97D5490AF0Q37962995-F162AEE8-2FBC-4C46-BF53-64BA1D683DDDQ38062443-FABE36BD-8966-48DB-B5BA-DE86EB56C669Q38085707-87FBB305-1F19-4C96-ACBB-0A69D082724FQ38151703-ED7534DF-F6A1-4513-A2EE-987702B81EA9Q38213709-02B42115-B33C-4FA8-BB79-D25C896F0703Q38300355-F2C3DFFA-068E-4653-A4DA-42AE7D5D6D6AQ39008914-88D51593-603A-4790-A7FA-774D3F8A91FAQ39062474-A10F44AD-7B9A-4A9F-82FB-44E6ADB10C99Q39596141-8B9B8352-DCCD-46AC-9E8F-EDBA3C2D7E2CQ41958818-1122927D-07BD-4B8E-A6DA-17C4AE7D8D2CQ42056580-88604461-20CD-4ED9-96B4-EF5356011DBCQ42968242-CB2256EE-3362-4AFF-892F-F898190A7B81Q46530393-7958004A-0C4A-4A2A-96FD-9EA691B31FA9Q50535284-0D613C3B-A1A2-4199-B7BF-C21608556583Q51009058-DBA72532-3F8C-4DCF-A052-491AC4FF8D16Q54222076-0DF4A113-F36A-49B0-A785-A67DAC35E965Q55406147-A29194FA-107B-4A14-8D7D-DC192F109D41
P2860
Differential expression of metabotropic glutamate receptors 2 and 3 in schizophrenia: a mechanism for antipsychotic drug action?
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Differential expression of met ...... for antipsychotic drug action?
@ast
Differential expression of met ...... for antipsychotic drug action?
@en
type
label
Differential expression of met ...... for antipsychotic drug action?
@ast
Differential expression of met ...... for antipsychotic drug action?
@en
prefLabel
Differential expression of met ...... for antipsychotic drug action?
@ast
Differential expression of met ...... for antipsychotic drug action?
@en
P2093
P2860
P1476
Differential expression of met ...... for antipsychotic drug action?
@en
P2093
Bryan W Potts
Carol A Tamminga
Kelly A Gleason
Kelly Lewis-Amezcua
Subroto Ghose
P2860
P304
P356
10.1176/APPI.AJP.2009.08091445
P407
P577
2009-06-01T00:00:00Z